Department of Surgery, Siauliai Cancer Center, Lithuania

Slides:

Advertisements

Similar presentations

EXPERT SYSTEM TECHNOLOGIES FOR DIAGNOSIS AND PROGNOSIS OF MALIGNANCIES Oleg Kshivets, MD, PhD Omsk Cancer Center, Thoracic Surgery Department, Russia.

Advertisements

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University.

1 1 Slide © 2008 Thomson South-Western. All Rights Reserved Chapter 15 Multiple Regression n Multiple Regression Model n Least Squares Method n Multiple.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.

Supplemental Figure 1 Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whiteney’s U-test. A. Expression.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Arterial spin labeling MR imaging of head and neck squamous cell carcinoma Abdel Razek A Department of Radiology Mansoura Faculty of medicine. Mansoura.

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer Zoran Gatalica1*, Jude.

Norwegian register for general thoracic surgery.

Patient & tumor characteristics (n=39)

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Wijendra Senarathne1, Peggy Gates1, Semir Vranic2, Zoran Gatalica1

Lung squamous cell carcinoma

DISTANT METASTASES OF LUNG CANCER AND IMMUNE SYSTEM

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.

Gender difference in age, risk factors and histological characteristics of lung cancer patients, presented to the Respiratory Unit of Teaching Hospital.

A Hussain, S Qadri, Y Haqzad, M Chaudhry, A Cale, M Cowen, M Loubani.

Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,

Lung Cancer Screening: Do Individual Health Beliefs Matter?

Prognosis of younger patients in non-small cell lung cancer

5-YEAR SURVIVAL OF UPPER THIRD ESOPHAGEAL CANCER PATIENTS WAS SIGNIFICANTLY SUPERIOR IN COMPARISON WITH MIDDLE AND LOWER THIRD ESOPHAGEAL CANCER PATIENTS.

Elizabeth A. David, MD, David T

Limburg Clinical Research Program

Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung

Results Results Introduction Objectives Conclusions

Diagnostic Surgical Pathology in Lung Cancer

Do tumor location and grade affect survival in pT2N0M0 esophageal squamous cell carcinoma? Dongrong Situ, MD, Junye Wang, MD, PhD, Peng Lin, MD, PhD,

Vulvar Cancer Women’s Hospital,School of Medicine Zhejiang University.

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Surgical–pathologic factors affect long-term outcomes in stage IB (pT2 N0 M0) non– small cell lung cancer: A heterogeneous disease Chung-Ping Hsu, MD,

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer Aritoshi Hattori, MD, Takeshi Matsunaga, MD, Kazuya.

Surgical Treatment of Metachronous Second Primary Lung Cancer

Somi Jacob and Christian Bach

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

Extended Sleeve Lobectomy: One More Step Toward Avoiding Pneumonectomy in Centrally Located Lung Cancer Jean-Philippe Berthet, MD, Marina Paradela, MD,

Survival and function after sleeve lobectomy for lung cancer

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

Innovative techniques for thoracoscopic lobectomy in postpneumonectomy patients Ryoichi Nakanishi, MD, PhD, Shinji Shinohara, MD, Kenji Muranaka, MD,

Carcinoma of the esophagus: Prognostic significance of histologic type

Volume 115, Issue 6, Pages (June 1999)

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Neal S Goldstein, MD The Annals of Thoracic Surgery

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Trends in survival from metastatic lung cancer in California,

Prognosis of angiosarcoma at different anatomic sites

Patients’ characteristics

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Surgical resection of metachronous liver metastases

Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.

Alexander H. Moskovitz, MD, Nabil P

Circulating Tumor Cells in Diagnosing Lung Cancer: Clinical and Morphologic Analysis Alfonso Fiorelli, MD, PhD, Marina Accardo, MD, Emanuele Carelli,

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

Department of Surgery, Siauliai Cancer Center, Lithuania Immunity Netwoks in Prediction of Five-Year Survival of Lung Cancer Patients after Radical Procedures Oleg Kshivets, M.D., Ph.D. Department of Surgery, Siauliai Cancer Center, Lithuania The First International Chicago Symposium on Malignancies of The Chest and Head & Neck Chicago, Illinois, The USA, 1999

Abstracts: Purpose: Influence of immunity networks on 5-year survival (5YS) of lung cancer (LC) patients (LCP) after a radical procedure (RP) was investigated. Methods: In randomized trial (1987-1998) cases after RP, monitored 108 LCP (males – 94, females – 14; pneumonectomy - 45, upper lobectomy - 44, lower lobectomy - 11, upper/lower bilobectomy - 5, middle lobectomy -1) with pathologic stage II-III (stage II – 34, stage III – 74; squamos cell LC - 56, adenocarcinoma - 46, large cell LC - 6; T1 - 38, T2 - 43, T3 – 23, T4 - 4; N0 – 63, N1 - 20, N2 - 25; G1 – 30, G2 – 34, G3 - 44) were reviewed. 59 LCP (age=56.7±0.9 years; tumor size: D=4.3±0.3 cm; life span: LS=1903.8±21.0 days) lived more than 5 years without any features of LC progressing. 49 LCP (age=56.6±1.2 years; D=4.6±0.3 cm; LS=542.7±55.2 days) died because of generalization of LC during the first 5 years after RP. Variables selected for 5YS study were input levels of 49 immunity blood parameters, sex, age, TNMG, cell type, D. Representativeness of samplings was reached by means of randomization based on unrepeated random selection. Multiple correspondence analysis (A), multi-factor clustering, A of variance, confirmatory factor A, structural equation modeling and Monte Carlo simulation were used to determine any significant overall regularity. Results: It was revealed that 5YS of LCP (n=108) after RP significantly depended on: 1) level of T-, B- and O-cell circuit; 2) value of monocyte- and macrophage-circuit; 3) level of humoral immunity; 4) ratio of malignant cell population quantity to immunity cell subpopulations in integral patient’s organism (cell ratio factors); 5) LC characteris-tics. Structural equation modeling and Monte Carlo simulation confirmed signifi-cant overall networks bet-ween 5YS (life span) of LCP after RP and cell immunity circuit (c2=7744.820;k=628; T=2.264;P=0.024), humoral immunity data (c2=20.328; k=13; T=3.496; P=0.0005), cell ratio factors (c2=446.462; k=65; T=13.258; P=0.0001e-9), LC characteristics (c2=69.514; k=19; T=4.520; P=0.00062e-2).

Samplings: Lung Cancer Patients Lived More than 5 Years after Radical Procedures……….59 Lung Cancer Patients Died Because Generalization During First 5 Years After Radical Procedures……………...49 In All……………………………… …108

Radical Procedures: Pneumonectomy…………………..45 Upper/Lower Bilobectomy……...…7 Upper Lobectomy………………....44 Lower Lobectomy………………....11 Middle Lobectomy………………….1 In All…………………………...…108

Staging: T1……38 N0……63 G1……30 T2……43 N1……20 G2……34 T4……..4 Stage II…34 Stage III...74 Squamous Cell Carcinoma……….....…56 Adenocarcinoma……………………….46 Large Cell Carcinoma…………………..6

Regularities between Lung Cancer Cell Population and Suvival:

Regularities between Immune System and 5-Year Survival Lung Cancer Patients:

Immune Homeostasis in Prognosis Lung Cancer Patients Survival:

Nucloids of Immune Cell Ratio Factors in Prognosis 5-Year Survival Lung Cancer Patients:

Correlations of Immune Cell Ratio Factors with Lung Cancer Patients Survival:

SEPATH-Model: Immune Cell Ratio Factors-Survival Lung Cancer Patients:

Immune Cell Ratio Factors in Prediction 5-Year Survival:

Logistic Regression Model: Immune Cell Ratio Factors-Survival Lung Cancer Patients:

Logistic Regression Model of System:Immune Cell Ratio Factors-Survival Lung Cancer Patients:

Models (T/CC, CD8+/CC and CD4+/CC, Lymph/CC-Life Span of LCP; n=49; 18th:P<0.01; 12th:P<0.001; 6th: P<0.05 and 18th: P<0.01 Degree Polynomial Fit): y=a+bx+cx2+dx 3+…

Regression Models (B/CC, O/CC and Mon/CC-Life Span of LCP; n=49; 18th: P<0.001;13th: P<0.01 and 18th: P<0.01 Degree Polynomial Fit): y=a+bx+cx2+dx 3+...

Regression Models (IgG, IgA and IgM-Life Span of LCP; n=49; 18th Degree Polynomial Fit): y=a+bx+cx2+dx 3+...

SEPATH-Models: Immune Cell Circuit-Lung Cancer Patients Survival:

Relationships between Immune Cell Subpopulations and Life Span of Lung Cancer Patients:

Immunity Networks and 5-Year Survival of Lung Cancer Patients

SEPATH-Models: Immune Homeostasis--Life Span of Lung Cancer Patients:

SEPATH-Models: Humoral Immunity, Cancer Cell Population-Life Span of Lung Cancer Patients:

Results of Monte Carlo Simulation:

Results of Monte Carlo Simulation: Cancer Cell Population--Survival:

Networks between Immune Cell Subpopulations, Cancer Cell Populations and 5-Year Survival Lung Cancer Patients:

Conclusions: 5-year survival and lifevspan of lung cancer patients after radical procedures significantly depended on: 1) level of T-, B- and O-cell circuit; 2) value of monocyte- and macrophage-circuit; 3) level of humoral immunity; 4) ratio of malignant cell population quantity to immunity cell subpopulations in integral patient’s organism (immune cell ratio factors); 5) cancer characteristics.

okshivets@yahoo.com kshivets@hotmail.com Oleg Kshivets, M.D., Ph.D. Thoracic/Abdominal Surgeon, Department of Surgery Siauliai Cancer Center, Tilzes:42-16, Siauliai, LT78206, Lithuania Tel. (37041)416614; Fax (37041)526430 okshivets@yahoo.com kshivets@hotmail.com http//:myprofile.cos.com/Kshivets